Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
Jay Backstrom has been named interim executive vice president of research and development for Acceleron Pharma. Backstrom previously served as vice president of global medical affairs and safety at Pharmion.
Shehnaaz Suliman has been named president and chief operating officer of Alector. Suliman brings experience from her previous role as senior vice president of corporate development and strategy at Theravance Biopharma.
Amylyx Pharmaceuticals has named Debra Canner as the company’s first global head of human resources. Canner was most recently appointed human resources consultant at CANbridge Pharmaceuticals.
Antares Pharma has bolstered its leadership with the appointment of Edward Tykot as senior vice president. Tykot previously served as the vice president of business development at Nevekar.
Scott Greenberg has been appointed vice president of business development and alliance management at Aro Biotherapeutics. Greenberg was most recently the vice president and head of operations at Roivant Sciences.
Biofrontera has named Christopher Pearson as the new chief commercial officer. Pearson was most recently vice president of commercial strategy and development at Aldeyra Therapeutics since 2018.
BridgeBio Pharma has named Eli Wallace chief scientific officer in residence for oncology. Wallace recently served as chief scientific officer at Peloton.
Bristol-Myers Squibb has named Kathryn Metcalfe as the new executive vice president of corporate affairs and Tim Power vice president and head of investor relations. Metcalfe was most recently the chief communications officer of CVS Health. Power has been the lead for investor relations at Bristol Meyers Squibb since 2016.
Jay Newmark has been named chief medical officer, Frank Jaeger has been appointed chief commercial officer, Jose Luis Rodriguez has been named the vice president of marketing, LaTonya Wright has been appointed the vice president of sales, and James Holloway has been named vice president of manufacturing and supply at Clarus Therapeutics. Newmark previously served as senior director of medical affairs at Genomic Health and OPKO Health. Jaeger was formerly the regional sales director at AbbVie. Rodriguez was formerly the head of the U.S. marketing oncology team for Astellas Pharmaceuticals. Wright was previously the regional sales director for Abbvie. Holloway was the lead for the research and development project management office at the infection prevention franchise of CareFusion, now BD Medical.
Ryan Spencer has been named chief executive officer and David Novack has been named the chief operating officer of Dynavax. Spencer’s most recent appointment was as senior vice president of commercial for Dynavax. Novack was the global head of technical operation, supply chain for diagnostics, and the global head of manufacturing strategy for vaccines at Novartis.
Steven King has been appointed prospective chief executive officer of EdgePoint AI, a division of Mateon Therapeutics. King was previously the CEO of Peregrine Pharmaceuticals.
Melissa Carpenter has been appointed chief scientific officer of regenerative medicine at ElevateBio. Carpenter previously served as the vice president of research and development at NovoCell.
Jan Adams has been named chief scientific officer at Gr?nenthal. Adams was previously the head of corporate strategy and portfolio management at Gr?nenthal before the promotion.
Bryson Goodwin has been named chief executive officer, Thomas Smeenk has been named the president, Natasha Server has been appointed the chief financial officer, and Yari Nieken will be appointed independent director for Hemostemix. Before joining Hemostemix, Goodwin was the managing director for Synergy Capital Market Advisors. Smeenk was most recently the president and CEO of Broadway Gold Mining. Server is a certified public accountant. Nieken is the founder of Foremost Capital and was formerly an investment adviser at Union Securities.
Locana has expanded its senior management team with the appointment of James Burns as chief executive officer. Burns was most recently CEO of Casebia.
Yvonne Li has been named senior vice president of finance and Brian Barnett has joined as vice president of clinical development at Nkarta Therapeutics. Li most recently served as the vice president of finance and the principal financial and accounting officer for OncoMed Pharmaceuticals. Barnett was previously the chief executive officer and the chief medical officer at OncBioMune Pharmaceuticals.
Northwest Biotherapeutics has named Jean Davis chief financial officer, chief accounting officer and interim chief information officer. Davis was formerly a risk advisory senior manager at BDO USA and is also a certified public accountant.
PMV Pharmaceuticals has appointed Leila Alland as chief medical officer. Alland last served as the CMO for Affimed.
Pyxis Oncology has announced a new addition to its leadership team with the appointment of Laura Sullivan as chief executive officer and director. Sullivan was previously the founder and president of SpringWorks Therapeutics.
Jean Franchi has been appointed chief financial officer at Replimune Group. Franchi was previously CFO for Merrimack Pharmaceuticals.
Shattuck Labs has appointed Casi DeYoung chief business officer. DeYoung formerly served as the chief operating officer at ImmuneSensor Therapeutics.
Frank DeRosa has been appointed chief technology officer, Michael Heartlein has been named executive vice president, and Paul Burgess will become the chief operating officer of Translate Bio. DeRosa was previously senior director of preclinical research and process development at Shire. Heartlein was previously the chief technology officer and founder of Translate Bio. Burgess was the senior legal adviser for Scholar Rock, Civitas Therapeutics and BIND Therapeutics.
Zelluna Immunotherapy has appointed Namir Hassan as chief executive officer. Hassan joined Zelluna in 2018 as the chief scientific officer.